Skip to main content

Market Overview

BioLineRx Announces Will Present Safety, Efficacy Clinical Data for Novel Stem Cell Mobilization Treatment at EHA

Share:

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that positive safety and efficacy Phase 1 clinical data of its lead clinical candidate, BL-8040, as a novel approach for mobilization and collection of bone-marrow stem cells from the peripheral blood circulation, will be presented in an oral presentation at the 20th Annual Congress of the European Hematology Association (EHA) to be held June 11-14, 2015 in Vienna, Austria. Data to be presented include response rates and additional pharmacodynamic studies done on the collected cells. In addition, positive preclinical data from studies supporting BL-8040's mechanism of action as a treatment for acute myeloid leukemia (AML) will be highlighted in a poster presentation. The molecular and cellular mechanisms by which BL-8040 affects AML cells will be presented.

BL-8040 will be featured in the following sessions:

(Abstract # S800) Monotherapy Treatment with a Single Dose of the CXCR4 Antagonist BL-8040 as a Novel Method for Mobilization of Human HSPC and MSC; Results of a Phase 1 Healthy Volunteers Study

Presenter: Yaron Pereg, PhD – Project Leader
Session: Stem Cell Transplantation: Clinical
Date and Time: Sunday, June 14, 8:00 a.m. – 8:15 a.m. CEST
Location: Room Lehar 1 + 2
(Abstract # P171) The CXCR4 Antagonist BL-8040 Directly Affects AML Blasts by Inducing their Terminal Differentiation and Blocking Survival Signals

Presenter: Yaron Pereg, PhD – Project Leader
Session: Acute Myeloid Leukemia - Biology
Date and Time: Friday, June 12, 5:15 p.m. – 6:45 p.m. CEST
Location: Poster area (Hall C)

 

Related Articles (BLRX)

View Comments and Join the Discussion!

Posted-In: News FDA Press Releases

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com